{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T07:34:54Z","timestamp":1794555294610,"version":"4.9.1"},"reference-count":28,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,24]],"date-time":"2019-12-24T00:00:00Z","timestamp":1577145600000},"content-version":"vor","delay-in-days":722,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1093\/annonc\/mdx680","type":"journal-article","created":{"date-parts":[[2017,10,16]],"date-time":"2017-10-16T15:13:27Z","timestamp":1508166807000},"page":"209-214","source":"Crossref","is-referenced-by-count":176,"title":["Phase II trial of pembrolizumab in patients with platinum refractory germ-cell tumors: a Hoosier Cancer Research Network Study GU14-206"],"prefix":"10.1016","volume":"29","author":[{"given":"N.","family":"Adra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.H.","family":"Einhorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.K.","family":"Althouse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.R.","family":"Ammakkanavar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Musapatika","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Albany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Vaughn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.H.","family":"Hanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"21","key":"10.1093\/annonc\/mdx680_bb0010","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1056\/NEJMra1407550","article-title":"Testicular cancer\u2013discoveries and updates","volume":"371","author":"Hanna","year":"2014","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1093\/annonc\/mdx680_bb0015","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1056\/NEJMoa067749","article-title":"High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors","volume":"357","author":"Einhorn","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdx680_bb0020","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1200\/JCO.2009.25.1561","article-title":"TI-CE high-dose chemotherapy for patients with previously treated germ cell tumors: results and prognostic factor analysis","volume":"28","author":"Feldman","year":"2010","journal-title":"J Clin Oncol"},{"issue":"27","key":"10.1093\/annonc\/mdx680_bb0025","doi-asserted-by":"crossref","first-page":"6549","DOI":"10.1200\/JCO.2005.19.638","article-title":"Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors","volume":"23","author":"Kondagunta","year":"2005","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1093\/annonc\/mdx680_bb0030","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1200\/JCO.1986.4.4.528","article-title":"VP-16 plus ifosfamide plus cisplatin as salvage therapy in refractory germ cell cancer","volume":"4","author":"Loehrer","year":"1986","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1093\/annonc\/mdx680_bb0035","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1200\/JCO.1998.16.7.2500","article-title":"Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor","volume":"16","author":"Loehrer","year":"1998","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1093\/annonc\/mdx680_bb0040","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1200\/JCO.1993.11.2.324","article-title":"Surgical salvage of chemorefractory germ cell tumors","volume":"11","author":"Murphy","year":"1993","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdx680_bb0045","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"New England Journal of Medicine"},{"issue":"19","key":"10.1093\/annonc\/mdx680_bb0050","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1093\/annonc\/mdx680_bb0055","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1093\/annonc\/mdx680_bb0060","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1093\/annonc\/mdx680_bb0065","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/bjc.2015.244","article-title":"Frequent PD-L1 expression in testicular germ cell tumors","volume":"113","author":"Fankhauser","year":"2015","journal-title":"Br J Cancer"},{"issue":"2","key":"10.1093\/annonc\/mdx680_bb0070","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1093\/annonc\/mdv574","article-title":"Prognostic value of programmed-death-1 receptor (PD-1) and its ligand 1 (PD-L1) in testicular germ cell tumors","volume":"27","author":"Cierna","year":"2016","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1093\/annonc\/mdx680_bb0075","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1093\/annonc\/mdw146","article-title":"Activity of immune checkpoint inhibition in platinum refractory germ-cell tumors","volume":"27","author":"Zsch\u00e4bitz","year":"2016","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1093\/annonc\/mdx680_bb0080","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"23","key":"10.1093\/annonc\/mdx680_bb0085","doi-asserted-by":"crossref","first-page":"7412","DOI":"10.1158\/1078-0432.CCR-09-1624","article-title":"Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria","volume":"15","author":"Wolchok","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1093\/annonc\/mdx680_bb0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","article-title":"Optimal two-stage designs for phase II clinical trials","volume":"10","author":"Simon","year":"1989","journal-title":"Control Clin Trials"},{"issue":"7","key":"10.1093\/annonc\/mdx680_bb0095","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1200\/JCO.2015.64.7909","article-title":"Conditional survival of patients with metastatic testicular germ cell tumors treated with first-line curative therapy","volume":"34","author":"Ko","year":"2016","journal-title":"J Clin Oncol"},{"issue":"Suppl 2S; abstr","key":"10.1093\/annonc\/mdx680_bb0100","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1200\/jco.2016.34.2_suppl.491","article-title":"Survival outcomes of patients with metastatic germ cell tumor (mGCT) treated from 1998 to 2012: the Indiana University (IU) experience","volume":"34","author":"Adra","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdx680_bb0105","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1200\/JCO.2016.69.5395","article-title":"High-dose chemotherapy and autologous peripheral-blood stem-cell transplantation for relapsed metastatic germ cell tumors: the Indiana University experience","volume":"35","author":"Adra","year":"2016","journal-title":"J Clin Oncol"},{"issue":"24","key":"10.1093\/annonc\/mdx680_bb0110","doi-asserted-by":"crossref","first-page":"4369","DOI":"10.1002\/cncr.29678","article-title":"Outcomes of postchemotherapy retroperitoneal lymph node dissection following high-dose chemotherapy with stem cell transplantation","volume":"121","author":"Cary","year":"2015","journal-title":"Cancer"},{"issue":"11","key":"10.1093\/annonc\/mdx680_bb0115","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1023\/A:1008365216323","article-title":"Cisplatin-refractory, HER2\/neu-expressing germ-cell cancer: induction of remission by the monoclonal antibody Trastuzumab","volume":"10","author":"Kollmannsberger","year":"1999","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1093\/annonc\/mdx680_bb0120","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1016\/j.ejca.2006.03.013","article-title":"Activity of thalidomide in patients with platinum-refractory germ-cell tumours","volume":"42","author":"Rick","year":"2006","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1093\/annonc\/mdx680_bb0125","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s10637-009-9280-2","article-title":"Phase II trial of sunitinib in patients with relapsed or refractory germ cell tumors","volume":"28","author":"Feldman","year":"2010","journal-title":"Invest New Drugs"},{"issue":"1","key":"10.1093\/annonc\/mdx680_bb0130","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1097\/01.coc.0000195086.47548.ef","article-title":"Phase II study of imatinib mesylate in chemotherapy refractory germ cell tumors expressing KIT","volume":"29","author":"Einhorn","year":"2006","journal-title":"Am J Clin Oncol"},{"issue":"6","key":"10.1093\/annonc\/mdx680_bb0135","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1093\/annonc\/mdx124","article-title":"Pazopanib in advanced germ cell tumors after chemotherapy failure: results of the open-label, single-arm, phase 2 Pazotest trial","volume":"28","author":"Necchi","year":"2017","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1093\/annonc\/mdx680_bb0140","doi-asserted-by":"crossref","first-page":"e65821","DOI":"10.1371\/journal.pone.0065821","article-title":"PTEN loss increases PD-L1 protein expression and affects the correlation between PD-L1 expression and clinical parameters in colorectal cancer","volume":"8","author":"Song","year":"2013","journal-title":"PLoS One"},{"issue":"2","key":"10.1093\/annonc\/mdx680_bb0145","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1158\/0008-5472.CAN-14-3362","article-title":"Control of PD-L1 expression by oncogenic activation of the AKT-mTOR pathway in non-small cell lung cancer","volume":"76","author":"Lastwika","year":"2016","journal-title":"Cancer Res"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419350033?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419350033?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/29\/1\/209\/23561086\/mdx680.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T04:42:59Z","timestamp":1624682579000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419350033"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["S0923753419350033"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdx680","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]}}}